Literature DB >> 24066760

Ibrutinib in relapsed chronic lymphocytic leukemia.

Stuart A Rushworth, David J MacEwan, Kristian M Bowles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24066760     DOI： 10.1056/NEJMc1309710

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

Review 1.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

2.  Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.

Authors:  Phillip L R Nicolson; Craig E Hughes; Stephanie Watson; Sophie H Nock; Alexander T Hardy; Callum N Watson; Samantha J Montague; Hayley Clifford; Aarnoud P Huissoon; Jean-Daniel Malcor; Mark R Thomas; Alice Y Pollitt; Michael G Tomlinson; Guy Pratt; Steve P Watson
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

3.  Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Authors:  Constantine S Tam; Sarah Kamel
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

4.  Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Andrew H Lipsky; Mohammed Z H Farooqui; Xin Tian; Sabrina Martyr; Ann M Cullinane; Khanh Nghiem; Clare Sun; Janet Valdez; Carsten U Niemann; Sarah E M Herman; Nakhle Saba; Susan Soto; Gerald Marti; Gulbu Uzel; Steve M Holland; Jay N Lozier; Adrian Wiestner
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

Review 5.  The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.

Authors:  Leslie J Crofford; Lindsay E Nyhoff; Jonathan H Sheehan; Peggy L Kendall
Journal:  Expert Rev Clin Immunol       Date:  2016-03-04       Impact factor: 4.473

6.  Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

Authors:  S Kamel; L Horton; L Ysebaert; M Levade; K Burbury; S Tan; M Cole-Sinclair; J Reynolds; R Filshie; S Schischka; A Khot; S Sandhu; M J Keating; H Nandurkar; C S Tam
Journal:  Leukemia       Date:  2014-08-20       Impact factor: 11.528

7.  Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.

Authors:  Nicolas Acquavella; David Clever; Zhiya Yu; Melody Roelke-Parker; Douglas C Palmer; Liqiang Xi; Holger Pflicke; Yun Ji; Alena Gros; Ken-Ichi Hanada; Ian S Goldlust; Gautam U Mehta; Christopher A Klebanoff; Joseph G Crompton; Madhusudhanan Sukumar; James J Morrow; Zulmarie Franco; Luca Gattinoni; Hui Liu; Ena Wang; Francesco Marincola; David F Stroncek; Chyi-Chia R Lee; Mark Raffeld; Marcus W Bosenberg; Rahul Roychoudhuri; Nicholas P Restifo
Journal:  Cancer Immunol Res       Date:  2014-10-30       Impact factor: 11.151

8.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

9.  Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.

Authors:  Gasim Dobie; Fahd A Kuriri; Musab M A Omar; Fehaid Alanazi; Ali M Gazwani; Chloe P S Tang; Daniel Man-Yuen Sze; Sasanka M Handunnetti; Constantine Tam; Denise E Jackson
Journal:  Blood Adv       Date:  2019-12-23

10.  Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.

Authors:  Scott A Ezell; Michele Mayo; Teeru Bihani; Suprawee Tepsuporn; Suping Wang; Melissa Passino; Shaun E Grosskurth; Mike Collins; Julie Parmentier; Corinne Reimer; Kate F Byth
Journal:  Oncotarget       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.